



Cancer Vaccines and Combination Immunotherapies

Guest Editors:

Dr. Jessica Chacon

Health Sciences Center, Texas
Tech University, Lubbock, TX
79409, USA

Dr. Richard Wu

Wexner Medical Center, Ohio
State University, Columbus, OH
43210, USA

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editors

Dear colleagues,

This Special Issue, titled “Cancer Immunotherapy: Vaccines and Combination Immunotherapies” will focus on fundamental research on cancer vaccines and combination immunotherapies. Special attention will be given to the topic of targeted cancer vaccines and combination immunotherapies aimed at modifying the tumor microenvironment, as well as the challenges associated with the development of these novel therapeutic approaches. We invite you to share original research articles as well as up to date reviews.

Research areas may include (but are not limited to) the following: neoantigen vaccines, cancer therapeutic vaccines, combination immunotherapy, DNA vaccines, dendritic cell-based vaccines, cell-based vaccines, nucleic-acid-based vaccines, neoadjuvant therapy, immune checkpoint therapy, nanoparticle immune therapy, anti-CTLA-4 therapy, anti-PDX therapy, and adoptive cell therapy.

We look forward to receiving your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com